These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859 [TBL] [Abstract][Full Text] [Related]
12. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894 [TBL] [Abstract][Full Text] [Related]
14. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515 [TBL] [Abstract][Full Text] [Related]
15. Mesalamine with MMX technology for the treatment of ulcerative colitis. Schreiber S; Kamm MA; Lichtenstein GR Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380 [TBL] [Abstract][Full Text] [Related]
16. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Sandborn WJ Am J Gastroenterol; 2002 Dec; 97(12):2939-41. PubMed ID: 12492172 [No Abstract] [Full Text] [Related]
17. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine. Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547 [TBL] [Abstract][Full Text] [Related]
18. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V; Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738 [TBL] [Abstract][Full Text] [Related]
19. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. Cohen HD; Das KM J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699 [TBL] [Abstract][Full Text] [Related]
20. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation]. MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443 [No Abstract] [Full Text] [Related] [Next] [New Search]